William Blair & Company
AVIR icon

William Blair & Company’s Atea Pharmaceuticals AVIR Stock Holding History

William Blair & Company’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52.7K Buy
11,325
+1,288
+13% +$6.41K ﹤0.01% 1768
2026
Q1 		$54K Buy
+10,037
New +$46.1K ﹤0.01% 1690
2023
Q4 		– Sell
-10,444
Closed -$31.3K – 1790
2023
Q3 		$31.3K Sell
10,444
-5
-0% -$17 ﹤0.01% 1635
2023
Q2 		$39.1K Sell
10,449
-5
-0% -$19 ﹤0.01% 1624
2023
Q1 		$35K Sell
10,454
-4
-0% -$16 ﹤0.01% 1629
2022
Q4 		$50.3K Buy
+10,458
New +$52.9K ﹤0.01% 1574
2022
Q3 		– Sell
-14,439
Closed -$103K – 1821
2022
Q2 		$103K Buy
+14,439
New +$98.6K ﹤0.01% 1538
2022
Q1 		– Sell
-28,869
Closed -$258K – 1911
2021
Q4 		$258K Sell
28,869
-53,944
-65% -$841K ﹤0.01% 1475
2021
Q3 		$2.9M Buy
82,813
+57,395
+226% +$1.59M 0.01% 603
2021
Q2 		$546K Buy
25,418
+16,438
+183% +$494K ﹤0.01% 1123
2021
Q1 		$555K Buy
8,980
+3,650
+68% +$247K ﹤0.01% 1082
2020
Q4 		$223K Buy
+5,330
New +$172K ﹤0.01% 1384

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

William Blair & Company's AVIR Position: Q2 2026 in Review

William Blair & Company increased its Atea Pharmaceuticals (AVIR) stake by 13% in Q2 2026, buying an estimated $6.41K and bringing the position to 11,325 shares worth $52.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1768.

William Blair & Company first reported a position in AVIR in Q4 2020 and has held it in 12 quarters since. The position peaked at $2.9M in Q3 2021. 124 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • William Blair & Company held 11,325 shares of Atea Pharmaceuticals worth $52.7K as of Q2 2026.
  • William Blair & Company bought 1,288 Atea Pharmaceuticals shares in Q2 2026, an estimated $6.41K.
  • Atea Pharmaceuticals made up ﹤0.01% of William Blair & Company's portfolio in Q2 2026, its #1768 holding.
  • William Blair & Company first reported a position in Atea Pharmaceuticals in Q4 2020 and has held it in 12 quarters since.
  • William Blair & Company's Atea Pharmaceuticals position peaked at $2.9M in Q3 2021.
  • 124 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on William Blair & Company's 13F filing for Q2 2026, filed 11 Aug 2026.